Well Referenced

Tag: neuropathic pain

Review of the neurological benefits of phytocannabinoids

This 2018 review by Maroon and Bost examines the therapeutic potential of phytocannabinoids, particularly cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ9-THC), in various neurological disorders. The authors highlight the neuroprotective, anti-inflammatory, and immunomodulatory properties of these compounds, which interact with the endocannabinoid system (ECS) to influence physiological processes. Clinical and preclinical studies

Read More »
June 26, 2025 No Comments

A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy

This 2018 systematic review examined the therapeutic role of alpha-lipoic acid (ALA) in diabetic polyneuropathy (DPN), focusing on efficacy, safety, and cost-effectiveness. Based on 25 studies, including randomized controlled and open-label trials, ALA administered at 600 mg/day—either intravenously or orally—consistently reduced neuropathic symptoms with minimal adverse effects. Mechanistically, ALA exerts

Read More »
June 26, 2025 No Comments

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials

This 2012 meta-analysis evaluated the efficacy of alpha-lipoic acid (ALA) in treating symptomatic peripheral neuropathy in diabetic patients. The analysis included randomized controlled trials using the Total Symptom Score (TSS) to assess outcomes. Results showed a significant reduction in TSS favoring ALA treatment, with both oral and intravenous forms proving

Read More »
June 26, 2025 No Comments

Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial

This 2021 monocentric, randomized, double-blind, placebo-controlled clinical trial published in Biomedicine & Pharmacotherapy (DOI: 10.1016/j.biopha.2021.112308, PMID: 34649217) evaluated the safety and efficacy of alpha-lipoic acid (ALA) supplementation for reducing chronic pain of unknown etiology. Involving 100 adult participants over 60 days, the study found that ALA significantly reduced pain intensity

Read More »
June 26, 2025 No Comments

Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial

The study titled Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial, published in Pain (2021), investigated the efficacy of alpha-lipoic acid (ALA) in reducing pain among fibromyalgia patients. This randomized controlled trial found that ALA significantly reduced pain scores compared to

Read More »
June 26, 2025 No Comments

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial

The study titled “The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial” (Diabetes Care, 2003, PMID: 12610036) is a randomized controlled trial investigating the effects of alpha-lipoic acid (ALA) on diabetic polyneuropathy. Involving 120 patients with type 2 diabetes and symptomatic polyneuropathy, participants received either

Read More »
June 26, 2025 No Comments

Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant Alpha-Lipoic Acid: A Meta-Analysis

The meta-analysis titled “Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis” (Diabet Med, 2004, PMID: 14984445) evaluated the efficacy and safety of intravenous alpha-lipoic acid (600 mg/day) over three weeks in diabetic patients with symptomatic polyneuropathy. Analyzing data from four randomized, double-masked, placebo-controlled trials (n=1,258), the

Read More »
June 26, 2025 No Comments